Search

You searched for "cardiovascular"

286 results found

Licence to save: a UK survey of anti-VEGF use for the eye

1 February 2017 | | EYE - Vitreo-Retinal
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

1 August 2015 | | EYE - Vitreo-Retinal
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...
Ophthalmologica journal cover image.

Displacement of submacular haemorrhage – comparative study pneumatic displacement versus subretinal cocktail injection

3 October 2024 | | EYE - Vitreo-Retinal
The authors report a multicentre retrospective interventional case series study comparing the outcome of submacular haemorrhage (SMH) using pneumatic displacement with intravitreal expansile gas versus treatment with pars plana vitrectomy (PPV) versus subretinal injection of tissue plasminogen activator (tPA), anti-vascular...

AI can identify treatment gaps for patients with macular disease, study shows

10 November 2025 | artificial intelligence, AMD, new studies, treatment analysis
Using artificial intelligence (AI) in eye clinics could reduce both undertreatment and overtreatment of neovascular or ‘wet’ age-related macular degeneration (AMD). AMD is the leading cause of irreversible vision loss in older people and accounts for around 1 in 10...

The approach to angle-closure glaucoma

1 October 2016 | | EYE - Glaucoma
Further to my last article in Eye News (print issue) describing the diagnostic approaches to various clinical scenarios in glaucoma, the approach to angle-closure glaucoma (ACG), a situation terrifying for patient and registrar alike, will be discussed. Please refer to...

25 years of OCT

1 December 2016 | | EYE - Vitreo-Retinal, EYE - Imaging
David Huang first described optical coherence tomography (OCT) in 1991, in his seminal paper on the subject in Science. This method developed the work of others on ophthalmic interferometry, which essentially showed that measuring reflected light could be used to...

Eye Capacity: clinical need should drive ophthalmic service provision

1 February 2014 |
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

Update on emerging therapies for age-related macular degeneration

4 December 2023 | | EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

More sensitive visual acuity test for age-related macular degeneration

1 October 2016 | | EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

The role of injection assistant devices in establishing a nurse-led AMD service

1 April 2018 | | EYE - Vitreo-Retinal
The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Corporate M&A pace gathers momentum

1 October 2019 | | EYE - General
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

A near miss

1 February 2019 | | EYE - Vitreo-Retinal, EYE - General
A 55-year-old gentleman presented with a ‘blurry patch’ to his left eye which he had noticed for the past two months. The visual acuity with correction was 6/5 in the right eye and 6/6 in the left eye on the...